Defining Optimal Therapeutic Strategies in T-Cell Lymphomas Through Pathway Inhibition, Immune Modulation, and Chemotherapy Refinement

T-cell lymphoma (TCL) is a rare and aggressive blood cancer that has seen little progress in treatment for decades. Unlike many other cancers, we still treat most TCL patients with the same strong chemotherapy, a "one-size-fits-all" approach. While this sometimes works at first, the cancer often returns and becomes resistant, leading to poor survival rates. The central problem is that we are not matching modern treatments to the unique biology of each patient's disease. My research program aims to change this by launching three targeted clinical trials that replace the old chemotherapy model with a new, "smarter" strategy.

Our first trial tests a new, targeted drug (named golidocitinib) for patients newly diagnosed with a common type of TCL. We are adding this pill, which blocks a specific "engine" of cancer growth inside the tumor cells, to standard treatment. Our goal is to see if this more precise approach can lead to more cures from the very beginning.

The second trial is for patients whose cancer has come back or stopped responding to treatment. We are testing a novel combination of two drugs: one designed to wake up the patient's own immune system to attack the cancer (pembrolizumab), and another that removes the "invisibility cloak" tumors use to hide (ruxolitinib). We believe this double-hit strategy will be a powerful new option for these difficult-to-treat patients.

The third trial addresses a very lethal subtype of TCL linked to a virus, which disproportionately affects certain populations. For this cancer, we don't even know which chemotherapy works best. We are using a global network of cancer centers to finally answer this fundamental question, establishing a stronger foundation so we can build better future treatments.

Success in this program will be measured by our ability to show these new treatments are safe and effective, improving patient outcomes. The longer-term goal is to use what we learn from the biology of each patient's tumor in these trials to create a roadmap for the future. We want to make precision medicine a reality for every TCL patient, ensuring that the right patient gets the right treatment at the right time. This research will provide new hope and better, smarter therapies for patients fighting this devastating disease now and in the years to come.